Ftse Mib
32.665,21
-2,81%
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
66.254,43
0,09%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Arcutis Biotherapeutics Inc (ARQT) Arcutis Biotherapeutics Inc (ARQT) Notizie

Arcutis Biotherapeutics Inc

ARQT
8,63
-0,71 (-7,60%)
15 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
10/6/202420:30GLOBEArcutis Announces New Long-Term Data of Roflumilast Cream..
06/6/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
05/6/202414:00GLOBEArcutis Announces Multiple Abstracts, Including Oral..
04/6/202420:03EDGAR2Form 144 - Report of proposed sale of securities
03/6/202414:00GLOBEArcutis to Present at the Goldman Sachs 45th Annual Global..
30/5/202401:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/5/202421:54EDGAR2Form 144 - Report of proposed sale of securities
28/5/202413:00PRNCAArcutis Canada annonce l'acceptation aux fins d'examen par..
20/5/202423:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202421:58EDGAR2Form 144 - Report of proposed sale of securities
14/5/202422:06EDGAR2Form 8-K - Current report
14/5/202422:00GLOBEArcutis Announces First Quarter 2024 Financial Results and..
14/5/202413:18IHMARKETNEWSUS Futures Remain Steady Amid Wall Street Caution Ahead of..
13/5/202414:00GLOBEExpert Panel Review Further Validates Use of ZORYVE®..
03/5/202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
29/4/202422:00GLOBEArcutis to Report First Quarter 2024 Financial Results..
10/4/202414:00GLOBEArcutis Appoints David Topper as Chief Financial Officer
05/4/202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
01/4/202413:00GLOBESol-Gel’s Collaboration Partner First-to-File ANDA Drug..
28/3/202413:00GLOBEArcutis to Present at the 23rd Annual Needham Virtual..
11/3/202413:00GLOBEArcutis Promotes Todd Tucker to Chief Human Resources..
10/3/202421:00GLOBEArcutis Presents Late-Breaking Data From INTEGUMENT-PED..
09/3/202422:00GLOBENew Research Reveals Genomic Profile of Seborrheic..
06/3/202423:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202423:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
04/3/202423:47EDGAR2Form 144 - Report of proposed sale of securities
04/3/202423:42EDGAR2Form 144 - Report of proposed sale of securities
04/3/202423:40EDGAR2Form 144 - Report of proposed sale of securities
04/3/202422:10EDGAR2Form 8-K - Current report
04/3/202422:00GLOBEArcutis Announces Closing of Public Offering of Common Stock..
04/3/202414:00GLOBEArcutis Announces Acceptance of Late Breaking Abstract in..
01/3/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202422:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/2/202423:00GLOBEArcutis to Present at the TD Cowen 44th Annual Health Care..
29/2/202405:30GLOBEArcutis Announces Pricing of $150 Million Public Offering
28/2/202422:54EDGAR2Form 144 - Report of proposed sale of securities
28/2/202422:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/2/202422:10EDGAR2Form 8-K - Current report
28/2/202422:10GLOBEArcutis Announces Proposed Public Offering
28/2/202422:00GLOBEArcutis and Sato Announce Strategic Collaboration and..
27/2/202422:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202413:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202413:44EDGAR2Form 8-K - Current report
27/2/202411:50GLOBEArcutis Announces Fourth Quarter and Full Year 2023..
16/2/202414:00GLOBEArcutis to Report Fourth Quarter and Full Year 2023..
16/2/202400:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 9,25 Min: 8,515 Max: 9,49
Chiusura: 9,34

La tua Cronologia

NASDAQ
ARQT
Arcutis Biotherapeutics
BITMOT
2652064
Btp Valore Sc Oct28 Eur
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network